Skip to Main Content

Author Details

Scott Kopetz
University of Texas MD Anderson Cancer Center
2000
439
90
PMIDPaper TitleJournal TitlePublished Year
37815847SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR <i>BRAF</i>V600E-mutant mCRC.Future Oncol2024
37943166Effects of KRAS Genetic Interactions on Outcomes in Cancers of the Lung, Pancreas, and Colorectum.Cancer Epidemiol Biomarkers Prev2024
37975903PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room.Clin Cancer Res2024
35195555Germline Cancer Risk Profiles of Patients With Young-Onset Colorectal Cancer: Findings From a Prospective Universal Germline Testing and Telegenetics Program.Dis Colon Rectum2023
38085001Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination.Cancer Res Commun2023
37487150Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Colorectal Cancer.JCO Precis Oncol2023
37848491Author Correction: Global proteomic identifies multiple cancer-related signaling pathways altered by a gut pathobiont associated with colorectal cancer.Sci Rep2023
37791069Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics.Front Cell Dev Biol2023
37696912Global proteomic identifies multiple cancer-related signaling pathways altered by a gut pathobiont associated with colorectal cancer.Sci Rep2023
37886575New Insights into Macrophage Polarization and its Prognostic Role in Patients with Colorectal Cancer Liver Metastasis.Res Sq2023
37827065Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer.Eur J Cancer2023
37824798Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing.JCO Precis Oncol2023
37932451CRISPR-Cas9-based functional interrogation of unconventional translatome reveals human cancer dependency on cryptic non-canonical open reading frames.Nat Struct Mol Biol2023
38040541Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial.EBioMedicine2023
37873318DeMixSC: a deconvolution framework that uses single-cell sequencing plus a small benchmark dataset for improved analysis of cell-type ratios in complex tissue samples.bioRxiv2023
37768068Oncogenic KRAS Drives Lipofibrogenesis to Promote Angiogenesis and Colon Cancer Progression.Cancer Discov2023
35797554Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases.Ann Surg2023
36952536Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo.PLoS One2023
37313712BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.Clin Trials2023
37311055A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.Oncologist2023
37310170Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.Mol Cancer Ther2023
37040395Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer.Clin Cancer Res2023
37465976Young-onset Rectal Cancer: Unique Tumoral Microbiome and Correlation With Response to Neoadjuvant Therapy.Ann Surg2023
36623241Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors.J Clin Oncol2023
36781990Survival improvement for patients with metastatic colorectal cancer over twenty years.NPJ Precis Oncol2023
36747713Combined KRAS<sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS<sup>G12C</sup>-driven cancers by addressing intrinsic and acquired resistance.bioRxiv2023
36646758EMP1<sup>+</sup> tumor cells drive metastatic relapse.Cell Res2023
36576431Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.Oncologist2023
36595731Reply to Y. Yu et al.J Clin Oncol2023
36067452Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).J Clin Oncol2023
36331676Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors.Invest New Drugs2023
36200910Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures.Oncologist2023
36200895Diverticular disease and cancer risk: More than a gut feeling.J Natl Cancer Inst2023
36351210Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in <i>RAS/RAF</i> Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy.J Clin Oncol2023
36319850Targeted exome-based predictors of patterns of progression of colorectal liver metastasis after percutaneous thermal ablation.Br J Cancer2023
36378102Truncal Dynamics May Trump: Serial ctDNA to Predict Early Therapeutic Response.Clin Cancer Res2023
34059508Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer.Gut2022
35653981Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.ESMO Open2022
35412613Precision Combination Therapies Based on Recurrent Oncogenic Coalterations.Cancer Discov2022
35508177Patient-derived micro-organospheres enable clinical precision oncology.Cell Stem Cell2022
35732135KRAS<sup>G12C</sup>-independent feedback activation of wild-type RAS constrains KRAS<sup>G12C</sup> inhibitor efficacy.Cell Rep2022
35703957Colorectal Liver Micrometastases: Association with RAS/TP53 Co-Mutation and Prognosis after Surgery.J Am Coll Surg2022
35472176Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.Oncologist2022
35608860Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review.JAMA Netw Open2022
35834757Reply to F. Dayyani et al.JCO Precis Oncol2022
35764271Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.Ann Oncol2022
35730192Endoscopy for the diagnosis and treatment of gastrointestinal bleeding caused by malignancy.J Gastroenterol Hepatol2022
35576377Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer.Br J Surg2022
35697807Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression.Nat Biotechnol2022
35862868Identification of <i>KRAS</i><sup><i>G12C</i></sup> Mutations in Circulating Tumor DNA in Patients With Cancer.JCO Precis Oncol2022
  • 1 - 50 of 439

Recommended Authors

Walid K Chatila
Memorial Sloan Kettering Cancer Center
Career Start Year 2017
Number of shared co-authors 15
Azfar Basunia
Memorial Sloan Kettering Cancer Center
Career Start Year 2017
Number of shared co-authors 0
Min Lu
Shangrao Hospital Affiliated to Nanchang University
Career Start Year 2016
Number of shared co-authors 1
Luai R Zarour
Oregon Health and Science University (OHSU)
Career Start Year 2010
Number of shared co-authors 1
Alexandra Drakaki
David Geffen School of Medicine at university of california los angeles
Career Start Year 2009
Number of shared co-authors 3
Eliezer M Van Allen
Dana-Farber Cancer Institute
Career Start Year 2009
Number of shared co-authors 29
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 4
Ashiq Masood
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Career Start Year 2008
Number of shared co-authors 1
Bishoy M Faltas
Sandra and Edward Meyer Cancer Center
Career Start Year 2007
Number of shared co-authors 3
Kjetil Boye
Oslo University Hospital
Career Start Year 2007
Number of shared co-authors 1
Stephen Welch
Victoria Hospital
Career Start Year 2007
Number of shared co-authors 7
Celina Ang
Tisch Cancer Institute, Mount Sinai Hospital
Career Start Year 2005
Number of shared co-authors 4
Kristel Kemper
Oncode Institute, The Netherlands Cancer Institute
Career Start Year 2005
Number of shared co-authors 7
Debyani Chakravarty
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 19
Itzhak Avital
Goldman School of Medicine, Ben Gurion University
Career Start Year 2001
Number of shared co-authors 1
Jes??s Garc??a-Donas
HM Hospitales-Centro Integral Oncologico Clara Campal
Career Start Year 2001
Number of shared co-authors 3
Manish A Shah
Weill Cornell University
Career Start Year 2000
Number of shared co-authors 5
Andrea Bertotti
Candiolo Cancer Institute - FPO IRCCS
Career Start Year 2000
Number of shared co-authors 9
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 1
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 15
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Career Start Year 1999
Number of shared co-authors 6
Joon Oh Park
Samsung Medical Center, Sungkyunkwan University School of Medicine
Career Start Year 1997
Number of shared co-authors 8
Sunil Sharma
Brody School of Medicine, East Carolina University
Career Start Year 1997
Number of shared co-authors 9
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 7
Remond J A Fijneman
The Netherlands Cancer Institute
Career Start Year 1993
Number of shared co-authors 8
Ultan McDermott
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 17
Suresh Nair
Lehigh Valley Topper Cancer Institute
Career Start Year 1990
Number of shared co-authors 8
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 9
Robyn L Ward
University of Sydney
Career Start Year 1989
Number of shared co-authors 6
Steven R Alberts
Mayo Clinic
Career Start Year 1987
Number of shared co-authors 10

Collaborators

Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Co-authored papers 40
Eduardo Vilar
The University of Texas MD Anderson Cancer Center
Co-authored papers 29
Jeffrey S Morris
Perelman School of Medicine, University of Pennsylvania
Co-authored papers 28
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Co-authored papers 18
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 15
Mark J Routbort
University of Texas MD Anderson Cancer Center
Co-authored papers 15
John Paul Shen
The University of Texas MD Anderson Cancer Center
Co-authored papers 14
Ganiraju C Manyam
the University of Texas MD Anderson Cancer Center
Co-authored papers 13
Ken Chen
University of Texas MD Anderson Cancer Center
Co-authored papers 11
Shailesh Advani
Co-authored papers 10
Michael A Davies
The University of Texas MD Anderson Cancer Center
Co-authored papers 10
Anil K Sood
The University of Texas MD Anderson Cancer Center
Co-authored papers 10
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Co-authored papers 10
Ernest T Hawk
The University of Texas MD Anderson Cancer Center
Co-authored papers 9
Hop S Tran Cao
Co-authored papers 8
Paul Scheet
University of Texas M.D. Anderson Cancer Center
Co-authored papers 8
Garth Powis
PHusis Therapeutics Inc.
Co-authored papers 7
Qingyi Wei
South China University of Technology
Co-authored papers 7
Shubham Pant
The University of Texas MD Anderson Cancer Center
Co-authored papers 6
Noralane M Lindor
Mayo Clinic
Co-authored papers 5
Cristina Ivan
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Kenneth R Hess
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Wayne W Grody
David Geffen School of Medicine, university of california los angeles
Co-authored papers 5
Rodrigo Dienstmann
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
Co-authored papers 5
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
AmirAli Talasaz
University of California San Diego Moores Cancer Center
Co-authored papers 5
Steven H Lin
University of Texas MD Anderson Cancer Center
Co-authored papers 4
Chen Hu
Johns Hopkins University School of Medicine
Co-authored papers 4
Wei Zhang
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
Timothy P Heffernan
Co-authored papers 4
Release 1.2